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Abstract
Introduction: As a group, women who carry germline mutations in partner and localizer of breast cancer 2
susceptibility protein (PALB2) are at increased risk of breast cancer. Little is known about by how much or whether
risk differs by mutation or family history, owing to the paucity of studies of cases unselected for family history.
Methods: We screened 1,403 case probands for PALB2 mutations in a population-based study of Australian women
with invasive breast cancer stratified by age at onset. The age-specific risk of breast cancer was estimated from the
cancer histories of first- and second-degree relatives of mutation-carrying probands using a modified segregation
analysis that included a polygenic modifier and was conditioned on the carrier case proband. Further screening for
PALB2 c.3113G > A (W1038X) was conducted for 779 families with multiple cases of breast cancer ascertained
through family cancer clinics in Australia and New Zealand and 764 population-based controls.
Results: We found five independent case probands in the population-based sample with the protein-truncating
mutation PALB2 c.3113G > A (W1038X); 2 of 695 were diagnosed before age 40 years and 3 of 708 were
diagnosed when between ages 40 and 59 years. Both of the two early-onset carrier case probands had very strong
family histories of breast cancer. Further testing found that the mutation segregated with breast cancer in these
families. No c.3113G > A (W1038X) carriers were found in 764 population-based unaffected controls. The hazard
ratio was estimated to be 30.1 (95% confidence interval (CI), 7.5 to 120; P < 0.0001), and the corresponding
cumulative risk estimates were 49% (95% CI, 15 to 93) to age 50 and 91% (95% CI, 44 to 100) to age 70. We found
another eight families carrying this mutation in 779 families with multiple cases of breast cancer ascertained
through family cancer clinics.
Conclusions: The PALB2 c.3113G > A mutation appears to be associated with substantial risks of breast cancer that
are of clinical relevance.
Introduction
An increasing number of so-called moderate-risk [1]
breast cancer susceptibility genes have been identified.
Protein-truncating mutations in ataxia telangiectasia
mutated (ATM), breast cancer type 1 susceptibility pro-
tein (BRCA1)-interacting protein 1 (BRIP1) and partner
and localizer of the breast cancer 2 early onset protein
(BRCA2) (PALB2), as well as CHK2 checkpoint homolog
(CHEK2), have been observed to be nearly 10 times
more likely in patients with strong breast cancer family
histories than in unaffected controls [2-4]. The implica-
tions of these observations are not straightforward, so it
is difficult to use the cancer histories of these families to
make informative estimates of risk (penetrance) when
the reason for studying them in the first place is their
family cancer history [2-5]. Inference is more informa-
tive when based on testing families unselected for family
history, but there is a paucity of such data for these
genes.
Predicated on the assumption that the increased risk
associated with a mutation multiplies a woman’s under-
lying familial genetic risk, for these genes it has been
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estimated that rare protein-truncating mutations are
associated with, on average, two- to threefold increases
in risk [1-4]. Therefore, this increased risk must be
interpreted by taking into account a carrier’s family his-
tory. Consequently, for a given gene, the absolute risk is
not the same for all carriers of such mutations [5].
It is also possible that the increased risk is not the
same for all mutations. Some mutations in moderate-
risk genes are high risk. For example, population-based
studies have shown that the 7217T > G variant in ATM
is associated with a substantially increased risk compar-
able to that for mutations in BRCA1 and BRCA2 [6], as
has a subset of rare substitutions in ATM [7]. Another
example is the Finnish founder PALB2 mutation; on the
basis of studying cases unselected for family history, it
has been estimated to be associated with a sixfold
increased risk and a cumulative breast cancer risk of
40% by age 70 years [8].
We tested Australian women affected and unaffected
by breast cancer and selected and unselected for family
history for PALB2 mutations to estimate the prevalence




The Australian Breast Cancer Family Registry (ABCFR)
is a population-based, case control family study of breast
cancer with an emphasis on early-onset breast cancer
that is being carried out in Melbourne and Sydney, Aus-
tralia [9-11], and is part of the Breast Cancer Family
Registry [12]. All adult women living in the metropoli-
tan areas of Melbourne and Sydney who were diagnosed
with a histologically confirmed first primary cancer of
the breast were invited to participate in the ABCFR.
From January 1, 1992, through September 30, 1999, in
Melbourne and from January 1, 1993, through Decem-
ber 31, 1998, in Sydney, women younger than 40 years
of age at diagnosis were selected; after January 1, 1996,
random samples of women ages 40-49 years and 50-59
years at diagnosis were selected. All recruitment was
done regardless of family history.
Cases were identified by use of the Victoria and New
South Wales cancer registries, to which notification of
cancer diagnoses is a legislative requirement. Overall, we
approached 2,303 eligible individuals (ages at diagnosis:
<40 years, 1,208; 40-49 years, 551; 50-59 years, 544),
which resulted in 1,610 cases, and blood samples were
collected from 94% of these cases. Cancer in relatives
was verified by cancer registry reports, medical records
or death certificates.
Previous mutation screening performed on the germ-
line DNA of these women included screening for
BRCA1, BRCA2, TP53 and ATM using a variety of
mutation detection techniques [13-20]. These identified
BRCA1 (n = 47), BRCA2 (n = 48), ATM (n = 1) and
tumor protein 53 (TP53) (n = 5) mutation carriers who
were not excluded from PALB2 mutation screening per-
formed in this study. Six hundred ninety-five women
under the age of 40 years diagnosed with breast cancer
were available from the ABCFR for high-resolution
melting (HRM) curve analysis of PALB2, and 708
women ages 40 years and over and diagnosed with
breast cancer were screened for PALB2 c.3113G > A
using the Custom TaqMan SNP Genotyping Assay
(Applied Biosystems, Carlsbad, CA, USA). The study
was approved by the ethics committees of The Univer-
sity of Melbourne and The Cancer Council Victoria,
and all participants provided written informed consent
for participation in the study.
The Kathleen Cuningham Foundation Consortium for
Research in Familial Breast Cancer (kConFab) collected
the same epidemiological, family history and lifestyle
data, as well as biospecimens, as the ABCFR from more
than 1,500 Australasian families with multiple cases of
breast encompassing 10,000 individuals gathered from
family cancer clinics in Australia and New Zealand [21].
For 778 families we obtained a DNA sample from the
youngest affected member who had provided a blood
sample and who had been tested and found not to carry
a BRCA1 or BRCA2 mutation. All participants provided
written informed consent for participation in the study.
High-resolution melting curve analysis and sequencing
analysis of PALB2
The PALB2 genomic sequence was obtained from the
National Center for Biotechnology Information (reference
sequence number NG_007406.1). Primers (Geneworks,
Hindmarsh, South Australia, Australia) (Additional file 1)
were designed by using Primer3 software (Whitehead
Institute and Howard Hughes Medical Institute, Cam-
bridge, MA, USA). For optimal performance of the HRM
curve analysis, primers were designed to amplify DNA
products between 100 and 310 bp. A total of 35 fragments
were designed to cover the coding and flanking intronic
regions of PALB2. The primer sequences and annealing
temperatures are listed in Additional file 2. Initially, 96
DNA were Sanger-sequenced as described in Tischkowitz
et al. [22]. These data and the corresponding DNA were
then used to establish the optimal conditions for HRM
curve analysis. DNA extracted from peripheral blood sam-
ples provided by 1,473 case probands (695 from women
diagnosed with breast cancer under the age of 40 years
participating in the ABCFR and 778 from kConFab) were
screened for germline PALB2 mutations using HRM curve
analysis [23,24]. DNA was then systematically screened
using this established method. HRM reactions were
carried out in 15-μL volumes and included 1.5 μL of
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10 × polymerase chain reaction (PCR) buffer (Applied Bio-
systems, Victoria, Australia), a 3 mM final concentration
of MgCl2 (Applied Biosystems), a 100 μM final concentra-
tion of deoxyribonucleotide triphosphate (dNTP) (Bioline,
Alexandria, New South Wales, Australia), a 200 nM final
concentration of each primer (Geneworks) (Additonal
File 2), a 2.3 μM final concentration of Syto9 (Invitrogen,
Victoria, Australia), 0.25 U of AmpliTaq Gold (Applied
Biosystems) and 3 μL of Q solution (Qiagen, Victoria,
Australia). Each reaction underwent a hold of 10 minutes
at 95°C and 40 cycles of amplification of 30 s at 95°C and
1 minute at annealing temperature followed by melting to
dissociate double-stranded DNA. The temperature range
for melting was set at ± 10°C of the melting temperature
of each amplicon with a rise in temperature of 0.05°C/s.
HRM analysis was performed using Rotor-Gene 6000 Ser-
ies Software 1.7 (Qiagen). Fragments displaying aberrant
melt curves were sequenced to determine potential under-
lying genetic variations. For sequencing reactions, we uti-
lized larger amplicons than those generated during HRM
curve analysis (Additional file 1). Sequencing was carried
out in 10-μL reactions, which included 1 μL of 10 × PCR
buffer (Applied Biosystems), a 3 mM final concentration
of MgCl2 (Applied Biosystems), a 100 μM final concentra-
tion of dNTP (Bioline), a 200 nM concentration of each
primer (Geneworks), 0.25 U of AmpliTaq Gold (Applied
Biosystems) and 3 μL of Q solution (Qiagen). PCR pro-
ducts were purified and analyzed on a 3130xl Genetic
Analyser (Applied Biosystems) and the results were viewed
using Chromas 1.45 (Technelusium, Tewantin, Queens-
land, Australia).
TaqMan assays
Using the methods of Orlando et al. [25] and Ratna-
singhe et al. [26], DNA extracted from the peripheral
blood of 708 ABCFR probands diagnosed with breast
cancer over the age of 40 years, 403 probands selected
from the kConFab resource and 764 unaffected popula-
tion controls from the ABCFR were analyzed for
PALB2, c.3113G > A using the TaqMan assay. Each
10-μL reaction contained 5 μL of 2 × TaqMan Genotyp-
ing Master Mix (Applied Biosystems) and 0.125 μL of
40 × Custom Taqman SNP Genotyping Assay mix
(Applied Biosystems), and the reactions were performed
using a LightCycler 480 SW1.5 (Roche, Penzberg,
Germany).
Statistical methods for penetrance analyses
The age-specific hazard ratio (HR) for breast cancer
(that is, the ratio of the age-specific breast cancer inci-
dence rates for carriers of the mutation to that for non-
carriers) was estimated using modified segregation
analysis [27]. Models were fitted by the method of maxi-
mum likelihood using the statistical package MENDEL
version 3.2 [28] (Department of Human Genetics,
UCLA School of Medicine, Los Angeles, California,
USA). To adjust for ascertainment, the likelihood for
each pedigree was conditioned on the proband’s pheno-
type (breast cancer status and age of onset) and geno-
type. Each pedigree involved data for the carrier
proband and her first- and second-degree relatives.
A mixed model was employed which incorporates an
unmeasured polygenic factor to model the effect on
breast cancer risk of a large number of unmeasured
genes in addition to the measured major gene [29]. The
polygenic part of this model was implemented via a
hypergeometric polygenic model with four loci [30] and
postulates a normally distributed random variable G for
each person so that these variables are correlated within
families (see section 8.9 of Lange et al. [31]). A woman’s
age at breast cancer diagnosis was modeled as a random
variable whose HR was, for noncarriers, exp(G) times
the Australian breast cancer incidence rate for 1992-
2002 [32] or, for carriers, the product of this HR multi-
plied by the age-specific HR. As in Antoniou et al. [33],
the variance of G was chosen to be 1.67, and the mean
was chosen so that the average HR for noncarriers
equaled the population incidence. When testing for an
age dependence of the HR, the model with a constant
HR was compared to one where the HR was a continu-
ous, piecewise linear function of age which was constant
before age 40 years, linear between ages 40 and 60 years
and constant after age 60 years.
All models assumed Hardy-Weinberg equilibrium at
the PALB2 locus, a dominant action of PALB2 c.3113
G > A on breast cancer risk, conditional independence
of all phenotypes given genotypes and an allele fre-
quency of 0.001 for the variant in the Australian popula-
tion. Two-sided P values for the modified segregation
analyses were based on the likelihood ratio test.
Age-specific cumulative risk estimates were calculated
from these HRs as one minus the exponential value of the
cumulative HR, and the corresponding confidence inter-
vals were calculated using a parametric bootstrap with
5,000 replications. More specifically, 5,000 draws were
taken from the normal distribution that the parameter
estimates would be expected to follow under asymptotic
likelihood theory. For each age, corresponding values of
the cumulative risk were calculated, and the 95% CI was
taken to be the 2.5th and 97.5th percentiles of this sample.
To test the accuracy of this estimate, we compared an
appropriate weighted average of the corresponding survi-
val functions (which are one minus the cumulative risk)
with the Kaplan-Meier survival curve [33].
Results
We tested for PALB2 mutations using HRM curve ana-
lysis to scan DNA extracted from peripheral blood
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samples taken from a sample unselected for family
history of women diagnosed with breast cancer before
the age of 40 years (probands) from a population-based
case control family study (ABCFR). Two of the 695 pro-
bands diagnosed before the age of 40 years were found
to carry the PALB2 c.3113G > A (W1038X) mutation,
and both had strong family histories of breast cancer.
Figure 1 shows that only 8% of all tested probands had
two or more first- or second-degree relatives with breast
or ovarian cancer [13], yet both these carriers were in
this extreme group.
Proband 1 was diagnosed at the age of 37 years with a
grade 3 infiltrating ductal carcinoma. Figure 2a shows
that proband 1 had three sisters who had all been diag-
nosed with breast cancer (one had two primary diag-
noses) at the ages of 36, 40, 45 and 51 years. Her
mother had been diagnosed with breast cancer at the
age of 68 years, and a maternal cousin had a breast can-
cer diagnosis at the age of 51 years. The proband’s
father had been diagnosed with bladder cancer at the
age of 65 years and prostate cancer at the age of 68
years. Two paternal aunts had breast cancer diagnoses
at ages 67 and 54 years, and a paternal cousin (the
daughter of an affected paternal aunt) had been diag-
nosed with breast cancer at the age of 47 years. Predic-
tive testing was performed for this PALB2 mutation
using blood samples collected from 22 family members.
Four affected female relatives were found to carry this
mutation (one was an obligate carrier) that involved the
paternal lineage. The proband’s mother, maternal uncle
and a maternal cousin with breast cancer did not carry
the mutation.
Proband 2 was diagnosed with a grade 3 infiltrating
ductal carcinoma at the age of 27 years. Figure 2b
shows that she had two paternal aunts diagnosed with
breast cancer at ages 34 and 35 years and a paternal
grandmother diagnosed at the age of 50 years (all
deceased). Predictive testing was performed for this
PALB2 mutation using blood samples collected from
seven family members as well as paraffin-embedded tis-
sue from three of the affected relatives (one paternal
aunt and two paternal grandparents). The proband’s
father and two affected female relatives related to the
father carried the mutation. One unaffected sister of the
proband, age 42 years at last contact, carried PALB2
c.3113G > A. The proband’s mother, a maternal aunt
and two sisters, all unaffected, did not carry the
mutation.
We then used a TaqMan assay to screen women diag-
nosed with breast cancer between the ages of 40 and 59
years and control probands participating in the ABCFR
for the PALB2 c.3113G > A mutation. One of the 360
probands diagnosed at age 40-49 years and 2 of 348
diagnosed at ages 50-59 years were found to carry the
mutation. Figures 2c-2d show that all of these carriers
had a family cancer history, and one included verified
reports of breast cancer in relatives. None of 764 tested
population-based controls carried this mutation.

Figure 1 Women diagnosed with breast cancer under age 40 years: The Australian Breast Cancer Family Registry. The majority of breast
cancer patients diagnosed before the age of 40 years have no affected family members (zero affected; the “sporadic” breast cancer group), some
probands have one affected family member (one affected), and ~8% have a stronger family history (the “familial” breast cancer group). A strong
family history is defined as the case proband having two or more first- or second-degree relatives affected by breast or ovarian cancer. x
represents the 22 partner and localizer of the breast cancer 2 early onset protein (BRCA2) mutation carriers identified by previous testing in the
ABCFR [13,19]. The filled black stars represent the two probands found to carry PALB2 c.3113G > A who both have a very strong family history of
breast cancer. Adapted from Hopper [42].
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Figure 2 Pedigrees of the PALB2 c.3113G > A mutation-carrying families. Pedigrees of the PALB2 c.3113G > A mutation carrying families
with (a) probands (indicated by arrows) and (b) families with probands diagnosed under the age of 40 years identified in the population-based
study. (c) Family with probands diagnosed under the age of 50 years and (d) families diagnosed under the age of 60 years. Breast cancer is
indicated by black filled symbols, and other cancers are indicated by gray filled symbols. All primary cancer diagnoses are indicated for each
individual. Numbers within symbols represent multiple individuals. Breast, breast cancer; V, cancer verified; +, PALB2 c.3113G > A-positive; -, PALB2
c.3113G > A-negative; (+), obligate carrier; /, deceased.
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Using the five population-based mutation carrier
families, we estimated the breast cancer HR using the
cancer histories of first- and second-degree relatives and
found it to be 30.1 (95% CI, 7.5-120; P < 0.0001), inde-
pendent of age (P = 0.8; though because of low power, a
modest age dependence cannot be ruled out). These
data corresponded to estimated age-specific cumulative
risk ratios (penetrance) of 49% (95% CI, 15-93) to age
50 years and 91% (95% CI, 44-100) to age 70 years (see
Figure 3). Our confidence in these estimates was
enhanced by their high degree of agreement with the
Kaplan-Meier survival curves for female first- and sec-
ond-degree relatives of the probands, which accounted
for the fact that these relatives are a mix of carriers and
noncarriers (see Figure 4). The HR corresponding to the
PALB2 W1038X variant could not be distinguished
from the average of the age-specific HRs for BRCA2
mutations reported by Antoniou et al. [34] of 13.6
(P = 0.3). It was higher than a HR of 2.3, which is
roughly equivalent to the odds ratio of 2.3 for PALB2
variants reported by Rahman et al. [4] (P = 0.0003).
HRM screening for PALB2 mutations for 779 families
with multiple cases of breast cancer recruited through
Australian and New Zealand clinics by the kConFab
consortium identified a further eight (1.0%) families that
carried the PALB2 c.3113G > A mutation. We did not
attempt to estimate penetrance using these family his-
tories, since they were nonsystematically selected by
their family histories of cancer.
Discussion
Studies conducted in the United Kingdom, Finland,
Italy, Spain and Canada have shown that, while rare,
mutations in PALB2 are far more common in breast
cancer patients with a strong family history than in
unaffected population-based controls. In the UK study,
Figure 3 Age-specific cumulative risks for PALB2 c.3113G > A mutation carriers. Age-specific cumulative risks of breast cancer for women
carrying the PALB2 c.3113G > A mutation (unbroken lines) and for women in the general Australian population (dotted line).
Southey et al. Breast Cancer Research 2010, 12:R109
http://breast-cancer-research.com/content/12/6/R109
Page 6 of 10
10 (1.1%) of 923 strongly familial cases, compared with
0 of 1,084 unaffected controls, were mutation carriers
(P = 0.004) [4]. The Finnish recurrent mutation PALB2
(c.1592delT) was carried by 3 (2.7%) of 113 familial
breast cancer cases compared with 6 (0.2%) of 2,501
controls, an 11-fold difference (95% CI, 3-44) [35]. A
French-Canadian founder mutation, c.2323C > T, result-
ing in Q775X, was found in 2 (0.6%) of 356 unselected
early-onset cases compared with 1 (2%) of 50 familial
cases and none (0%) of 6442 newborns [36]. Papi et al.
[37] screened 132 Italian families with breast cancer
without BRCA1 or BRCA2 mutations and identified one
protein-truncating mutation (c.2257C > T, R753X) that
was not observed in 300 control DNA. Garcia et al. [38]
reported one protein-truncating mutation (c.1056-
1057delGA, K3531X) in a screen of 95 families with
multiple cases of breast cancer without BRCA1 or
BRCA2 mutations. These observations, while showing
Figure 4 The Kaplan-Meier survival curves for PALB2 c.3113G > A mutation carriers. The Kaplan-Meier survival curve with breast cancer as
the outcome for female first- and second-degree relatives of the probands with the fitted survival curve overlaid. The fitted survival curve was
calculated as the average of the survival curves for carriers and noncarriers, each of these being equal to the exponential minus the appropriate
cumulative incidences. For the averaging of survival curves, we used age-specific weights equal to the expected proportion of relatives at risk of
breast cancer at a given age who carry (for the carrier survival curve) or do not carry (for the noncarrier survival curve) the partner and localizer
of breast cancer 2 susceptibility protein (PALB2) mutation. Carrier probabilities for the relatives were calculated from known genotypes and family
relationships, but not from affected status or other phenotypes, using a modified version of Mendel 3.2 software [28].
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that PALB2 mutations are associated with an increased
risk of breast cancer, cannot be used to obtain direct
or precise estimates of the magnitude of increased
risk [4,5].
Estimation of the average increased risk associated with
PALB2 mutations has been performed previously using
an indirect method by presuming a polygenic modifier
model. This method estimated that, on average, PALB2
protein-truncating mutations conferred a 2.3-fold
increased risk of breast cancer (95% CI, 1.4-3.9; P =
0.0025) [4]. For one specific Finnish founder mutation, a
direct estimate was made from a sample of population-
based cases unselected for family history and screened
for the PALB2 1592delT mutation [8]. Eighteen (0.9%) of
the 1,918 cases carried the mutation. It was estimated
from their family histories that carriers in this setting are
at about six times the general population risk (95% CI,
2-17; P = 0.01), equivalent to a breast cancer risk of 40%
by age 70 years (95% CI, 17-77), which is comparable to
the 45% estimate found for BRCA2 mutation carriers in a
large study of unselected carrier families [34].
In Australia, a PALB2 mutation has been found,
c.3113G > A, carried by 5 (0.4%) of 1,403 unselected
population-based patients diagnosed before age 60 years,
8 (1%) of 779 cases from families with multiple cases of
breast cancer, and none of 764 unaffected population-
based controls. This mutation was found twice in a UK
study [4] that screened 923 cases from families with
multiple cases of breast cancer. The Australian carrier
families reported here are predominantly of Australian,
English and Scottish heritage. These are the only reports
of this mutation we know of, so it is possible that this
mutation originated in the United Kingdom.
We estimated from analyses of case carrier families
that carriers of the PALB2 c.3113G > A mutation who
are relatives of unselected case carriers have a high risk
of developing breast cancer: about 50% to age 50 years
and 90% to age 70 years. The lower bound of the 95%
CI of the latter estimate is about the same as the aver-
age risk for BRCA2 mutation carriers estimated using
the same design and statistical methodology [39]. There-
fore, this mutation is associated with as high a risk as
other mutations being tested for by cancer family genet-
ics services across the world.
For families with multiple cases of breast cancer cur-
rently attending cancer genetics services in Australia, at
most 20% of those screened for BRCA1 and BRCA2 are
found to carry mutations [21], which is similar to the
rates in the United Kingdom [40] and the United States
[41]. Although PALB2 c.3113G > A is rare, testing for it
is inexpensive and has clinical utility. By virtue of being
based on case families, our risk estimate applies to
women with at least some family history, so it is appro-
priate for counseling carriers identified in families with
multiple cases of breast cancer who use cancer family
genetics services.
Conclusions
Given that carriers of this PALB2 mutation appear to be
at least at the conventional level of high risk, thought to
apply to BRCA1 and BRCA2 mutation carriers, testing
would seem justified in a clinical genetics setting. For
the women and their family members who carry these
mutations, it is potentially important that they be identi-
fied so that they can be offered appropriate prevention,
screening and clinical management. There may be other
PALB2 mutations that are also as highly penetrant, and
this paradigm might apply to other genes, such at ATM,
BRIP1 and CHEK2, for which mutations appear to be
associated, on average, with moderately increased risks,
but for which some mutations might be associated with
high risk. Targeted clinical testing of such high-risk
mutations in these genes could be justified.
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